This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/news/524142-cancer-covid-trojan-horse-adenovirus/
The article has changed 3 times. There is an RSS feed of changes available.
| Version 0 | Version 1 |
|---|---|
| Cutting-edge ‘Trojan horse’ tech that makes cancer tumors destroy themselves may work to treat Covid-19 too | Cutting-edge ‘Trojan horse’ tech that makes cancer tumors destroy themselves may work to treat Covid-19 too |
| (4 months later) | |
| Researchers at the University of Zurich have developed a technology that could not only cause cancer tumors to kill themselves, but could also potentially eradicate Covid-19 in people’s lungs. | Researchers at the University of Zurich have developed a technology that could not only cause cancer tumors to kill themselves, but could also potentially eradicate Covid-19 in people’s lungs. |
| The team used a modified adenovirus – a common type of respiratory virus that is often repurposed and used extensively in medical treatments as a delivery mechanism. The technology, known as SHielded, REtargeted ADenovirus (SHREAD), is akin to a Trojan horse in that it evades detection from the body’s own immune system and delivers genetic instructions for therapeutic antibodies directly into the tumor cells themselves. | The team used a modified adenovirus – a common type of respiratory virus that is often repurposed and used extensively in medical treatments as a delivery mechanism. The technology, known as SHielded, REtargeted ADenovirus (SHREAD), is akin to a Trojan horse in that it evades detection from the body’s own immune system and delivers genetic instructions for therapeutic antibodies directly into the tumor cells themselves. |
| The tumors then begin to mass produce their own doom in the form of antibody cells that eventually consume and eliminate the tumor, but with significantly lowered side effects compared to traditional cancer treatments. | The tumors then begin to mass produce their own doom in the form of antibody cells that eventually consume and eliminate the tumor, but with significantly lowered side effects compared to traditional cancer treatments. |
| “We trick the tumor into eliminating itself through the production of anti-cancer agents by its own cells,” says postdoctoral fellow Sheena Smith, who led the development of the technology at Zurich University. | “We trick the tumor into eliminating itself through the production of anti-cancer agents by its own cells,” says postdoctoral fellow Sheena Smith, who led the development of the technology at Zurich University. |
| A key element of this technique is that the therapeutic agents mostly stay in place and do not float off elsewhere in the body, thus sparing healthy organs and tissues from any collateral damage. The technologies that guide the adenovirus ‘Trojan horses’ to the right place in the body while hiding them from the immune system act almost like a precision-guided weapon. | A key element of this technique is that the therapeutic agents mostly stay in place and do not float off elsewhere in the body, thus sparing healthy organs and tissues from any collateral damage. The technologies that guide the adenovirus ‘Trojan horses’ to the right place in the body while hiding them from the immune system act almost like a precision-guided weapon. |
| In laboratory tests on mice, the scientists tricked a cancer tumor into producing trastuzumab, a clinically approved breast cancer antibody. Furthermore, the tumor actually produced more of the antibody over time, accelerating its own demise. Concentrations of trastuzumab away from the tumor, in tissues and the bloodstream, were low, indicating the reduced potential for side effects, confirmed by high-resolution 3D imaging observations. | In laboratory tests on mice, the scientists tricked a cancer tumor into producing trastuzumab, a clinically approved breast cancer antibody. Furthermore, the tumor actually produced more of the antibody over time, accelerating its own demise. Concentrations of trastuzumab away from the tumor, in tissues and the bloodstream, were low, indicating the reduced potential for side effects, confirmed by high-resolution 3D imaging observations. |
| The cutting-edge technology could mark the arrival of a highly effective delivery system for powerful drugs that would otherwise inflict too much damage. | The cutting-edge technology could mark the arrival of a highly effective delivery system for powerful drugs that would otherwise inflict too much damage. |
| Adenovirus vectors are currently being deployed in the Johnson & Johnson, AstraZeneca and Russian Sputnik V Covid-19 vaccines, but without the SHREAD technology. The Zurich researchers believe they could create an inhaled aerosol that could allow for targeted production of Covid-19 antibodies within the lung cells themselves. | Adenovirus vectors are currently being deployed in the Johnson & Johnson, AstraZeneca and Russian Sputnik V Covid-19 vaccines, but without the SHREAD technology. The Zurich researchers believe they could create an inhaled aerosol that could allow for targeted production of Covid-19 antibodies within the lung cells themselves. |
| “This would reduce costs and increase accessibility of Covid therapies, and also improve vaccine delivery with the inhalation approach,” Smith says. | “This would reduce costs and increase accessibility of Covid therapies, and also improve vaccine delivery with the inhalation approach,” Smith says. |
| Think your friends would be interested? Share this story! | Think your friends would be interested? Share this story! |
| Dear readers and commenters, | |
| We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system. | |
| Sorry for the inconvenience, and looking forward to your future comments, | |
| RT Team. |